Screener
Dianthus Therapeutics DNTH Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Capital expenditures | (10) | (24) |
| Purchases of investment securities | (238,588) | (67,324) |
| Proceeds from sales and maturities of investment securities | 104,625 | 82,142 |
| Net cash (used in)/provided by investing activities | (133,973) | 14,794 |
| Cash flows from financing activities: | ||
| Proceeds from public offering | 677,624 | — |
| Payment of issuance costs in connection with public offering | (1,343) | — |
| Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs | 58,731 | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's investing cash flow?
- Dianthus Therapeutics (DNTH) reported investing cash flow of -$133.97M in Q1 2026.
- How has Dianthus Therapeutics's investing cash flow changed year-over-year?
- Dianthus Therapeutics's investing cash flow decreased by 1005.6% year-over-year, from $14.79M to -$133.97M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Dianthus Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude